Cargando…

A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma

Our previous phase II study of cisplatin and gemcitabine in malignant mesothelioma showed a 47.6% (95% CI 26.2–69.0%) response rate with symptom improvement in responding patients. Here we confirm these findings in a multicentre setting, and assess the effect of this treatment on quality of life and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nowak, A K, Byrne, M J, Williamson, R, Ryan, G, Segal, A, Fielding, D, Mitchell, P, Musk, A W, Robinson, B W S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2002
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376155/ https://www.ncbi.nlm.nih.gov/pubmed/12189542 http://dx.doi.org/10.1038/sj.bjc.6600505

Ejemplares similares

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
por: van Haarst, J M W, et al.
Publicado: (2002)

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Overexpression and altered glycosylation of MUC1 in malignant mesothelioma
por: Creaney, J, et al.
Publicado: (2008)

p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression
por: Creaney, J, et al.
Publicado: (2001)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
por: Walsh, Christine S., et al.
Publicado: (2021)

Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma
por: Muruganandan, Sanjeevan, et al.
Publicado: (2017)

Statins Do Not Alter the Incidence of Mesothelioma in Asbestos Exposed Mice or Humans
por: Robinson, Cleo, et al.
Publicado: (2014)

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
por: Stemmler, H J, et al.
Publicado: (2011)

Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer
por: Millar, J, et al.
Publicado: (2005)

Efficacy, Safety, and Cost-Minimization Analysis of Continuous Infusion of Low-Dose Gemcitabine Plus Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
por: Arrieta, Oscar, et al.
Publicado: (2021)

A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas
por: Lee, J K, et al.
Publicado: (2013)

First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial
por: Arrieta, Ó, et al.
Publicado: (2012)

Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
por: Lee, Kyung-Hun, et al.
Publicado: (2021)

A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma
por: Eickhoff, A, et al.
Publicado: (2006)

ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
por: Morré, D. James, et al.
Publicado: (2016)

Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study
por: Xanthopoulos, Athanasios, et al.
Publicado: (2008)

BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
por: Guazzelli, Alice, et al.
Publicado: (2019)

Multicentric study on malignant pleural mesothelioma and non-occupational exposure to asbestos
por: Magnani, C, et al.
Publicado: (2000)

A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma
por: Bydder, S, et al.
Publicado: (2004)

Erratum to: ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
por: Morré, D. James, et al.
Publicado: (2016)

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
por: Goudar, Ranjit K
Publicado: (2008)

Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma
por: Borchert, Sabrina, et al.
Publicado: (2020)

MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions
por: Birnie, Kimberly A., et al.
Publicado: (2019)

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study
por: Valle, J W, et al.
Publicado: (2009)

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
por: Okusaka, T, et al.
Publicado: (2010)

The Investigation of Effects of Quercetin and Its Combination with Cisplatin on Malignant Mesothelioma Cells In Vitro
por: Demiroglu-Zergeroglu, A., et al.
Publicado: (2010)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Miyamoto, Yosuke, et al.
Publicado: (2021)

RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin
por: Muñoz-Montaño, Wendy, et al.
Publicado: (2021)

Discovery of new biomarkers for malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2015)

Orphan Designation and Cisplatin/Hyaluronan Complex in an Intracavitary Film for Malignant Mesothelioma
por: Banella, Sabrina, et al.
Publicado: (2021)

Cerebral metastases of malignant mesothelioma
por: Bathini, Abhijith, et al.
Publicado: (2022)

Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials
por: Wagner, A D, et al.
Publicado: (2009)

Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells
por: Johansson, D, et al.
Publicado: (2010)

Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine—A Randomized Phase II Trial
por: Markussen, Alice, et al.
Publicado: (2020)

Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients
por: Atzpodien, J, et al.
Publicado: (2007)

A Phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer
por: Doval, D C, et al.
Publicado: (2004)

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
por: Sørensen, J B, et al.
Publicado: (2008)

A Case Report of Primary Pericardial Malignant Mesothelioma Treated with Pemetrexed and Cisplatin
por: Kim, Jung Sun, et al.
Publicado: (2017)

SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma
por: Salaroglio, Iris Chiara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5tb8gvv1tjfrk2d5hkqahio40f